Key Quantitative Figures

Standalone Financial Results (Q2 FY2027 vs Q2 FY2026):

  • Revenue from Operations: ₹1,510.44 lakhs (vs ₹509.84 lakhs in Q2 FY2026)
  • Other Income: ₹102.16 lakhs (vs ₹138.21 lakhs in Q2 FY2026)
  • Total Revenue: ₹1,612.59 lakhs (vs ₹648.05 lakhs in Q2 FY2026)
  • Total Expenses: ₹1,308.07 lakhs (vs ₹471.74 lakhs in Q2 FY2026)
  • Profit Before Tax: ₹304.52 lakhs (vs ₹176.31 lakhs in Q2 FY2026)
  • Tax Expense: ₹50.72 lakhs (vs ₹53.46 lakhs in Q2 FY2026)
  • Net Profit: ₹253.81 lakhs (vs ₹122.85 lakhs in Q2 FY2026)
  • Basic EPS: ₹1.38 (vs ₹0.68 in Q2 FY2026)
  • Diluted EPS: ₹1.38 (vs ₹0.68 in Q2 FY2026)

Standalone Financial Results (H1 FY2027 vs H1 FY2026):

  • Revenue from Operations: ₹2,646.75 lakhs (vs ₹1,466.46 lakhs in H1 FY2026)
  • Other Income: ₹203.13 lakhs (vs ₹287.16 lakhs in H1 FY2026)
  • Total Revenue: ₹2,849.97 lakhs (vs ₹1,753.62 lakhs in H1 FY2026)
  • Total Expenses: ₹2,455.92 lakhs (vs ₹1,141.19 lakhs in H1 FY2026)
  • Profit Before Tax: ₹393.96 lakhs (vs ₹612.43 lakhs in H1 FY2026)
  • Tax Expense: ₹71.07 lakhs (vs ₹189.07 lakhs in H1 FY2026)
  • Net Profit: ₹322.89 lakhs (vs ₹423.36 lakhs in H1 FY2026)
  • Basic EPS: ₹1.75 (vs ₹2.36 in H1 FY2026)
  • Diluted EPS: ₹1.75 (vs ₹2.36 in H1 FY2026)

Segment-wise Revenue (Q2 FY2027):

  • Manufacturing: ₹1,033.73 lakhs
  • Project Sales: ₹476.71 lakhs
  • Unallocated: ₹102.16 lakhs

Segment-wise Profit Before Tax (Q2 FY2027):

  • Manufacturing: ₹265.97 lakhs
  • Project Sales: ₹22.60 lakhs
  • Unallocated: ₹27.96 lakhs

Capital Employed by Segment (as of September 30, 2026):

  • Manufacturing: ₹3,615.37 lakhs
  • Project Sales: ₹1,667.24 lakhs
  • Unallocated: ₹5,827.59 lakhs

Cash Flow Statement (H1 FY2027):

  • Net Cash Used in Operating Activities: ₹(254.97) lakhs
  • Net Cash Used in Investing Activities: ₹593.12 lakhs
  • Net Cash Used in Financing Activities: ₹(14.49) lakhs
  • Net Increase in Cash: ₹862.58 lakhs
  • Cash and Cash Equivalents at End: ₹5,231.29 lakhs

Balance Sheet Highlights (as of September 30, 2026):

  • Total Assets: ₹11,939.76 lakhs
  • Equity Share Capital: ₹1,843.73 lakhs
  • Other Equity: ₹9,266.47 lakhs
  • Total Equity: ₹11,110.20 lakhs
  • Total Liabilities: ₹829.56 lakhs

Dates of Action

  • Board Meeting Date: November 12, 2026
  • Meeting Commencement: 03:18 PM
  • Meeting Conclusion: 03:50 PM
  • Financial Period: Quarter and Half Year ended September 30, 2026
  • Preferential Issue Fund Raise Date: March 27, 2026

Parties Involved

  • Listed Entity: Chemtech Industrial Valves Limited
  • Stock Exchange: BSE Limited
  • Statutory Auditor: M/s. Raju & Prasad, Chartered Accountants
  • Compliance Officer: Aarohi Pareek, Company Secretary & Compliance Officer
  • Chairman: Pradeep Marsh (DIN: 00676715)

Purpose or Stated Rationale

The Board meeting was convened to approve the unaudited financial results for the quarter and half year ended September 30, 2026, as required under SEBI LODR Regulations.

Financial Impact Disclosure

The financial results show significant YoY growth in Q2 FY2027 revenue and profitability, while H1 FY2027 shows revenue growth but lower profitability compared to H1 FY2026. The company has utilized ₹35,59,33,582 out of the ₹57,25,00,000 raised through preferential issues for long-term funding needs.

Capital Structure Impact

No change in share capital reported during the period. Paid-up equity share capital remained at ₹1,843.73 lakhs with face value of ₹10.00 per share.

Cash Flow Implications

The company generated negative cash flow from operations (₹254.97 lakhs), used cash in investing activities (₹593.12 lakhs), and had minor cash outflow from financing activities (₹14.49 lakhs), resulting in a net cash increase of ₹862.58 lakhs for H1 FY2027.

Forward-looking Guidance

No forward-looking guidance or management commentary was provided in the disclosure.

Deviation Statement

The company declared no material deviation in the use of proceeds (₹7.5 crore) raised through the conversion of warrants into equity shares pursuant to the preferential issue. The funds were used for long-term funding for capital expenditure, working capital, and general corporate purposes as stated in the offer document.